Enabling technologies

#Academic #Analysis #Assay development optimisation & technology #Business #Cellular assays #Chemistry #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Metabolomics #Microbiome #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Metabolon and DNA Genotek collaborate on microbiome sampling solution for metabolomics

25 June 2020 Metabolon and DNA Genotek have teamed up to create OMNImet-GUT, said to be the first device for in-home collection and ambient-temperature storage and shipping of faecal samples for metabolomics, to the research market. “For years, our customers from across biopharma, academia and… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Dotmatics acquires BioBright to accelerate laboratory data automation

25 June 2020 Dotmatics has agreed to acquire BioBright, an expert in automating the flow of data from laboratory instruments to a secure cloud. BioBright’s solutions enable scientists to automate the collection of data from in-house and externally networked sources, and then standardise and analyse crucial experimental data… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Precision medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

PrecisionLife identifies 68 genes associated with risk of severe COVID-19

Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Epidarex announces £100 million UK venture fund to back life science firms

22 June 2020 Epidarex Capital, an international finance firm, has launched a £102 million fund in Edinburgh to invest in emerging life sciences businesses. The fund will build new life science companies using world-class research and innovation from emerging hubs across the UK, including university spinouts. Typical initial investments… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Regulatory #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

CatalYm to present data on immunotherapy of cancer at AACR Annual Meeting

19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Pharmacology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago

AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More

#Covid-19 #News

#Academic #Biomarkers #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Mobidiag receives second tranche of financing from European Investment Bank

17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular assays #Drug discovery #Enabling technologies #Lead discovery #Precision medicine #Regenerative Medicine #Screening #System biology #Systems biology #Toxicology

Qkine to accelerate commercial operations with US$1.9 million investment

09 June, 2020 The specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications announced the successful closure of a £1.5 million (US$1.9 million) series A investment round to accelerate the global scale-up of its commercial operations. According to Cambridge based Qkine, the funding… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered… Read More

#Exclusive Content

#Academic #Assay development optimisation & technology #Business #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #RNA #Target validation #Therapeutics

The Reproducibility Crisis – How did we get here?

By Dr William Olds and Dr Deepa Shankar While the antibody market has evolved into a multibillion-dollar industry enabling the discovery of cures, disease diagnosis and basic science acceleration, this has allowed low quality antibodies to hit the market. With a large crisis in reproducibility, the need for… Read More

#Exclusive Content

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Screening #Target validation #Toxicology

Getting a handle on liquids: automation solutions for drug discovery

Getting a handle on liquids: automation solutions for drug discovery By Helen Stewart-Miller and Thomas Hope The accurate and precise measurement of liquids and the transport of exact volumes between vessels, or from one instrument to another, are processes that constitute the very essence of research. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

2030 Life Sciences and Health in the Digital Age (Part 2)

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #Preclinical #RNA #Screening #System biology #Systems biology

Evolution of User Experience for life sciences

Evolution of User Experience for life sciences By Jacek Ziemski, Simon Fortenbacher, James Hoeksma, Jan Taubert, Roger Attrill, Paula de Matos, Andre Richter and Julie Morrison Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Oncology #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Oncology #Regulatory #Screening #Sequencing #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal… driving stronger biomarker-based… Read More

#Archive

Bacteriophage
#AI / data analytics / healthtech / informatics #Animal models #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Oncology #Preclinical #Stem cells #System biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Bitten by the Bug – A flurry of investments fuel microbiome drug discovery

By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To… Read More

#Archive